Rege Nephro Co., Ltd. (Headquarters: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) is pleased to announce its selection for the “Strengthening Program for Pharmaceutical Startup Ecosystem (Call for Proposals from Drug Discovery Ventures) (9th round)” for the following research and development project:
“Development of a Cell Therapy for Chronic Kidney Disease using Human iPS Cell-derived Nephron Progenitor Cells”

Details: https://www.amed.go.jp/koubo/19/02/1902C_00068.html

This program is a support initiative led by the Japan Agency for Medical Research and Development (AMED).
The program provides subsidies for development costs to drug discovery ventures that are in the preclinical to Phase II clinical trial stage, provided that they have received investment from a certified venture capital firm.
This initiative aims to resolve the significant fundraising challenges faced by Japanese drug discovery ventures and accelerate the commercialization of innovative vaccines and therapeutic drugs. It also actively supports ventures with a focus on global expansion, not just the Japanese market.

Under this program, Rege Nephro is supported by the following certified venture capital firms: DCI Partners Co., Ltd. as the Lead Certified Venture Capital Firm, and JIC Venture Growth Investments Co., Ltd., Kyoto University Innovation Capital Co., Ltd., JAFCO Group Co., Ltd., and Mitsubishi UFJ Capital Co., Ltd. as the Follower Certified Venture Capital Firms.

With this selection, Rege Nephro will further advance the development of a cell therapy for chronic kidney disease using human iPS cell-derived nephron progenitor cells, accelerating non-clinical and clinical studies toward its eventual clinical application.

Media Inquiries:
Mariko Iwamura
Rege Nephro Co., Ltd.
TEL: +81-75-744-6858
E-mail: info@regenephro.co.jp